Nanoviricides Stock Price, News & Analysis

NanoViricides (NYSE:NNVC) will present at the BIO International Convention 2025 in Boston on June 16th at 2:30pm. The company's President, Dr. Anil R. Diwan, will provide updates on their drug pipeline and platform technologies. Their lead drug candidate, NV-387, is advancing towards Phase II trials for MPOX treatment and shows effectiveness against RSV, Influenza A, and Coronaviruses. The drug's unique mechanism mimics host-side features that 90-95% of human pathogens use, making it difficult for viruses to develop resistance. The company is also developing NV-HHV-1 for herpesvirus infections and NV-HIV-1 for HIV treatment. NanoViricides' platform enables oral drug delivery, drug rescue, and targeted delivery capabilities. The estimated market size for NV-387 indications exceeds $10 billion.

NanoViricides (NYSE:NNVC) has filed its Q1 2025 quarterly report, highlighting significant progress with its broad-spectrum antiviral drug NV-387. The company is advancing towards Phase II clinical trials for treating MPox in the Democratic Republic of Congo, following successful completion of Phase I trials with no adverse events. NV-387 has shown promising results against multiple viruses including MPox, Measles, and Bird Flu (H5N1). The company reported $2.73M in cash and $6.98M in property assets, with current liabilities of $1.20M. However, NanoViricides needs additional funding to continue operations through February 2026 for planned clinical trials. The company has access to a $3M credit line from its founder and is exploring ATM equity offerings for funding.

NV-387's unique host-mimetic mechanism makes it potentially effective against various viruses while being difficult for viruses to develop resistance, positioning it as a potentially revolutionary treatment comparable to penicillin's impact on bacterial infections.

NanoViricides (NYSE:NNVC) is advancing its broad-spectrum antiviral drug NV-387 to combat multiple viral threats. The company is targeting two major opportunities: Measles, where cases have increased 10-fold in Europe with concerning vaccine failure rates, and MPox, which remains a Public Health Emergency of International Concern according to WHO.

The company has initiated an animal efficacy study for Measles and received clearance from DRC's National Ethics Committee to proceed with Phase II Clinical Trial for MPox treatment. NV-387 will be available to licensed physicians for treating Measles cases under FDA's Individual Patient Expanded Access protocol.

Additionally, NanoViricides is developing NV-387 as an "emperic" treatment for respiratory viral infections through a "basket-type" clinical trial targeting All Influenzas, All Coronaviruses, and RSV. The company is also developing NV-HHV-1, a pan-herpesvirus drug targeting infections linked to neurological damage and Alzheimer's disease.

NanoViricides (NYSE:NNVC) has received approval from the Democratic Republic of Congo's National Ethics Committee for Health to proceed with a Phase II clinical trial for NV-387, their broad-spectrum antiviral drug targeting MPox disease. The company is now preparing a detailed Clinical Trial Application for submission to DRC's Ministry of Public Health. NV-387 is designed to mimic human cells to trap and destroy viruses, potentially targeting 90-95% of human pathogenic viruses. The drug has shown promising results in animal studies against multiple viruses including influenza, RSV, coronavirus, and orthopoxvirus. Unlike existing treatments such as tecovirimat (which failed in clinical trials), NV-387's unique host-mimetic mechanism makes viral escape highly unlikely. This development is particularly significant as MPox continues to spread in the WHO African Region, maintaining its Public Health Emergency of International Concern status since August 2024.

NanoViricides (NYSE: NNVC), a clinical-stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology, has announced its participation in the D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. Company President & Executive Chairman Anil R. Diwan will be available for one-on-one meetings from 9:00 A.M. to 3:00 P.M. (ET). Interested parties can schedule meetings by contacting John Perez at jperez@dboralcapital.com.

NanoViricides announces progress in developing a potential treatment for measles as the disease threatens to become endemic in the USA. The company's drug candidate NV-387, a broad-spectrum antiviral, shows promise in targeting measles and related viruses like RSV.

Key developments:

• Stanford scientists predict measles becoming endemic due to declining vaccination rates
• 884 confirmed measles cases reported across 30 jurisdictions as of April 24, 2025
• 11% hospitalization rate with 3 fatalities
• NV-387 completed Phase I trials with no adverse events
• Company acquired measles virus and plans animal model studies

The company highlights vaccination challenges, including public trust issues post-COVID-19 and increasing population segments ineligible for vaccines. NV-387's mechanism mimics HSPG to act as a viral decoy, potentially effective against multiple viruses including measles, RSV, influenza, and COVID-19.

NanoViricides (NYSE:NNVC) has announced the evaluation of its clinical drug NV-387 for treating Measles virus amid a growing outbreak. The drug, which has completed Phase I trials with no adverse events, has shown effectiveness against multiple viruses that use HSPG for infection, including RSV, COVID-19, Influenza, and MPox.

According to CDC data as of April 11, 2025, there are 712 confirmed Measles cases, with 79 hospitalizations (11%) and 3 deaths. The company is open to enabling NV-387's use under FDA's 'Emergency Expanded Access for an Individual Patient' protocols. NanoViricides plans additional laboratory studies to evaluate NV-387's effectiveness against Measles in cell culture and animal models to support a future IND application.

The company argues that vaccination alone may not be sufficient to control outbreaks, citing a 28% vaccine failure rate among hospitalized cases and the need for 95-97% coverage for herd immunity.

NanoViricides (NYSE:NNVC) addresses recent stock price decline, emphasizing its immunity to tariffs and government spending cuts. The company's lead drug candidate, NV-387, is a broad-spectrum antiviral showing promise against multiple viruses including measles, RSV, MPox, and influenza.

The company is preparing for a Phase II clinical trial of NV-387 for MPox treatment in Central Africa. NV-387's unique mechanism mimics host-side signatures that viruses target, potentially effective against 90% of human pathogenic viruses. The company also highlights NV-HHV-1, their herpesvirus antiviral candidate, and NV-HIV-1 for HIV/AIDS treatment.

Management believes the recent stock decline alongside market sell-off is misguided, positioning NNVC as a potential hedge against market turmoil due to its strong long-term prospects in antiviral drug development.

NanoViricides (NNVC) announces its drug candidate NV-387 as a potential treatment for the ongoing measles outbreak, addressing HHS Secretary Kennedy's concern about the lack of approved antivirals. The broad-spectrum antiviral has shown effectiveness against various viruses that use heparan sulfate proteoglycans (HSPG) during cell infection.

The company believes NV-387 could be effective against measles based on two key factors: (1) studies indicating measles virus uses HSPG during cell infection, and (2) its success in treating RSV, which belongs to the same virus family as measles. NanoViricides proposes an investigator-initiated clinical trial to evaluate NV-387 as a measles treatment within FDA regulatory framework.

The announcement comes amid concerns about vaccine effectiveness against new measles variants, with the current Texas outbreak showing that even some vaccinated children are being hospitalized. The outbreak strain (genotype D.8) differs from the vaccine strain (genotype A), highlighting the need for effective treatment options.